Minerva Neurosciences logo
View printer-friendly version << Back
November 13, 2015

Minerva Neurosciences to Present at Jefferies 2015 London Healthcare Conference on November 18, 2015

WALTHAM, Mass., Nov. 13, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies 2015 London Healthcare Conference on November 18, 2015 at 9:00 a.m. Eastern Time.



The presentation will be web cast and accessible through the investor relations section of the Company's web site, http://ir.minervaneurosciences.com.  



About Minerva Neurosciences:



Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat CNS diseases. Minerva's proprietary compounds include: MIN-101, in Phase IIb development for schizophrenia; MIN-202 (JNJ-42847922), in Phase IIa and Phase Ib development for insomnia and adjunctive major depressive disorder (MDD), respectively; MIN-117, in Phase IIa development for MDD; and MIN-301, in pre-clinical development for the treatment of Parkinson's disease. Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV." For more information, please visit www.minervaneurosciences.com. 
CONTACT: William B. Boni

VP, Investor Relations/

Corp. Communications

Minerva Neurosciences, Inc.

 (617) 600-7376




This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Minerva Neurosciences, Inc. via Globenewswire

HUG#1966794

News Provided by Acquire Media